THE ROLE OF NANOTECHNOLOGY IN PHARMACEUTICAL DEVELOPMENT

Abstract

Numerous NMEs with unfavorable biologic and physicochemical characteristics that result in subpar pharmacokinetics and distribution following in vivo injection were chosen for full-scale development due to their pharmacological and safety findings.    These NMEs can be transformed into treatments more rapidly if preformulation studies are designed to provide a dosage form with the right drug delivery mechanism to meet desired pharmacokinetic and toxicological parameters.   The molecule's biopharmaceutics and pharmacokinetics can be altered to produce the desired druglike properties by nanoparticulate drug delivery methods.Improved systemic administration potential and site-specific delivery, which lowers unwanted toxicity from nonspecific dispersion, boosts patient compliance, and yields favorable therapeutic outcomes, are two advantages of using nanoparticulate drug delivery techniques.